A phase 2 study of itacitinib for the prevention of cytokine release syndrome (CRS) induced by immune effector cell (IEC) therapy: preliminary resultsM. J. Frigault, R. T. Maziarz, A. Lazaryan, N. V. Frey, A. Assal,N. N. Shah, L. J. Lekakis,J. H. Park, C. L. Phillips,L. Burke, M. Lakshminarayanan, R. Morariu-Zamfir,J. F. DiPersioBONE MARROW TRANSPLANTATION（2022）引用 0|浏览1暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
